BioCentury
ARTICLE | Company News

Chromocell, Astellas deal

October 5, 2015 7:00 AM UTC

Chromocell granted Astellas exclusive, worldwide rights to develop and commercialize the biotech’s CC8464 and backup candidates for pain. Chromocell plans to submit an IND for CC8464 in early 2016 and to lead development of the oral, peripherally acting Nav1.7 (SCN9A) antagonist through a Phase IIa trial in neuropathic pain. Astellas will lead all further development in the indication. ...